New Roads Ahead: Bipartisan Infrastructure Law Funding Announced
Client Alert | 2 min read | 10.19.22
Last week, the Department of Transportation (DOT) announced nearly $60 billion of funding available to states through DOT formula grant programs in fiscal year (FY) 2023. States may use these funds, authorized under the Bipartisan Infrastructure Law, to support critical infrastructure, including roads, bridges, and environmental and safety improvements. The FY2023 grant funds represent a substantial increase from FY2021. In particular, states will see an increase in grant funds for highway and bridge projects:
Significantly Increased Formula Program
|
Percentage increase over FY21 |
|
391% | |
|
146% | |
|
New | |
|
Highway Safety Improvement Program |
26% |
|
Metropolitan Planning Program |
25% |
|
Carbon Reduction Program |
New |
|
Promoting Resilient Operations for Transformative, Efficient, and Cost-Saving Transportation Formula (“PROTECT”) Program |
New |
|
National Highway Performance Program |
20% |
|
Surface Transportation Block Grant Program |
16% |
The Bipartisan Infrastructure Law also created three new programs to support carbon reduction, make transportation infrastructure more resilient to future weather events and other natural disasters, and promote use of electronic vehicles.
Companies interested in working on contracts under these grants should monitor infrastructure funding at the federal and state level to determine where, and how, it creates business opportunities. We are continuing to closely tracking the implementation of the Bipartisan Infrastructure Law to help clients navigate the unprecedented levels of infrastructure funding taking place this year, and over the next four years.
Contacts
Partner
She/Her/Hers
Counsel
She/Her/Hers
Insights
Client Alert | 3 min read | 06.30.25
The New EU “Pharma Package”: Preparing for the Trilogues
On June 4, 2025, after nearly two years of intense debate and negotiation between the 27 EU Member States, the Council of the European Union adopted its position on the proposed overhaul of the EU general pharmaceutical legislative framework known as the new Pharma Package.
Client Alert | 3 min read | 06.26.25
FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”
Client Alert | 3 min read | 06.26.25
Client Alert | 4 min read | 06.26.25
Ninth Circuit Affirms that CIPA Only Applies to Third-Party Eavesdropping
